Literature DB >> 2653935

Effect of interferon on glucose tolerance and insulin sensitivity.

V A Koivisto1, R Pelkonen, K Cantell.   

Abstract

Many viral infections induce interferon (IFN) production and cause insulin resistance. To examine the causal relationship between IFN and insulin resistance, we injected natural human leukocyte IFN-alpha (3 x 10(6) IU, i.m.) twice overnight in eight healthy subjects and determined oral (OGT) and intravenous (IVGT) glucose tolerance and sensitivity to insulin (287 nmol or 40 mU.m-2.min-1 euglycemic insulin clamp) the following morning. IFN caused mild influenzalike symptoms and induced a rise in circulating glucose, insulin, hydrocortisone (cortisol), growth hormone, and glucagon concentrations (P less than .05-.001). In the OGT test, the area under the glucose curve was 2.6-fold greater (P less than .02), and the disappearance rate of intravenously administered glucose was reduced by 28% (P less than .05) after IFN administration. The impairment in OGT and IVGT occurred despite augmented insulin response. Insulin-stimulated glucose disposal was reduced by 22% (P less than .005), and insulin clearance increased by 18% (P less than .02) after IFN administration. When the insulin-clamp study was repeated in patients with steady-state hyperinsulinemia that was 12% higher (P less than .005) after IFN, the glucose disposal rate was still reduced by 15% (P less than .01). These data indicate that IFN 1) stimulates counterregulatory hormone secretion, 2) impairs glucose tolerance and insulin sensitivity, and 3) stimulates insulin clearance. Thus, IFN may be involved in the development of insulin resistance during viral infections.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2653935     DOI: 10.2337/diab.38.5.641

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  29 in total

Review 1.  Diabetes mellitus during interferon therapy for chronic viral hepatitis.

Authors:  Ali Mofredj; Mehran Howaizi; Denis Grasset; Henri Licht; Sylvie Loison; Bruno Devergie; Renato Demontis; Jean-François Cadranel
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199

Review 2.  Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights.

Authors:  Gül Bahtiyar; John J Shin; Ayse Aytaman; James R Sowers; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2004-06       Impact factor: 4.810

3.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

4.  Rapidly reversible increase in insulin requirement with interferon.

Authors:  S Campbell; E H Mclaren; B J Danesh
Journal:  BMJ       Date:  1996-07-13

Review 5.  Interferon alpha: The key trigger of type 1 diabetes.

Authors:  Angela Lombardi; Effie Tsomos; Sara S Hammerstad; Yaron Tomer
Journal:  J Autoimmun       Date:  2018-08-14       Impact factor: 7.094

Review 6.  Emerging roles of JAK-STAT signaling pathways in adipocytes.

Authors:  Allison J Richard; Jacqueline M Stephens
Journal:  Trends Endocrinol Metab       Date:  2011-05-10       Impact factor: 12.015

Review 7.  Hepatitis C virus infection and type 1 and type 2 diabetes mellitus.

Authors:  Alessandro Antonelli; Silvia Martina Ferrari; Dilia Giuggioli; Andrea Di Domenicantonio; Ilaria Ruffilli; Alda Corrado; Silvia Fabiani; Santino Marchi; Clodoveo Ferri; Ele Ferrannini; Poupak Fallahi
Journal:  World J Diabetes       Date:  2014-10-15

8.  Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance.

Authors:  Hong Joo Kim; Jung Ho Park; Dong Il Park; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim
Journal:  Gut Liver       Date:  2009-06-30       Impact factor: 4.519

9.  Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C.

Authors:  Aspasia S Soultati; Spyridon P Dourakis; Alexandra Alexopoulou; Melanie Deutsch; Athanasios J Archimandritis
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

10.  Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance.

Authors:  Francesco Negro
Journal:  PPAR Res       Date:  2009-01-06       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.